Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company’s BPZE1 intranasal pertussis vaccine as well as other development and manufacturing activities. The company said that the new funding brings the total for development of BPZE1 to more than $100 million.
Iliad acquired rights to the pertussis vaccine from French research institute Inserm in 2014. The FDA granted Fast Track designation to BPZE1 earlier this year.
Iliad CEO Keith Rubin commented, “We are very pleased to close the $42.8M Class D investment which will allow ILiAD to continue to progress the development of our leading next generation pertussis vaccine. From day one, the importance of inducing mucosal immunity has been central to ILiAD’s mission to achieve global eradication of disease due to B. pertussis and it’s gratifying that key investors, public health agencies and leaders in the field of infectious disease are recognizing its pivotal role.”
Read the Iliad Biotechnology press release.
